Miravirsen

Drug Profile

Miravirsen

Alternative Names: Liver-specific microRNA-122 antagonist - Roche; LNA-antimiR™-122; miR-122 antagonist - Roche; Miravirsen sodium; SPC-3649

Latest Information Update: 22 Sep 2015

Price : $50

At a glance

  • Originator Santaris Pharma
  • Developer Roche
  • Class Antivirals; Oligonucleotides; RNA
  • Mechanism of Action MIRN122 microRNA inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • On Fast track

    Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Phase II Hepatitis C

Most Recent Events

  • 22 Sep 2015 Phase-II development for Hepatitis C (Treatment-naive) is ongoing in Germany, Netherlands, Poland, Puerto Rico, Slovakia and USA
  • 21 Sep 2015 Phase-II development for Hepatitis C (Treatment-experienced) is ongoing in USA and Puerto Rico (SC)
  • 01 Jun 2013 Santaris initiates enrolment in a phase II trial in Hepatitis C (treatment-experienced patients) in USA and Puerto Rico (NCT01872936)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top